{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:06:24Z","timestamp":1792033584503,"version":"4.4.0"},"reference-count":61,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the last years, a growing amount of evidence has been produced regarding the role of leukocytosis as a risk factor for thrombosis in patients with myeloproliferative neoplasms, predominantly in polycythemia vera (PV) and essential thrombocythemia (ET). Results from epidemiologic studies on this issue, however, are inconclusive. We conducted a systematic review and meta-analysis of articles published in the last 12 years addressing the issue, according to a predefined protocol. Forty-one articles analyzing &amp;gt;30\u2009000 patients met our inclusion criteria and were deemed of acceptable methodologic quality. In addition to data on thrombosis, data were collected on bleeding, hematologic evolution, secondary cancer, and death. The relative risk (RR) of thrombosis in the presence of leukocytosis was 1.59 (95% CI, 1.40-1.80), mainly accounted for by ET (RR, 1.65; 95% CI, 1.43-1.91) and arterial thrombosis (RR, 1.45; 95% CI, 1.13-1.86) subgroups; the effect was not significant in venous thrombosis alone. Sensitivity analyses considering recurrent events as well as white blood cell estimates adjusted or unadjusted for confounding factors confirmed the primary results. In addition, the pooled RR of studies that tested white blood cell counts in time-dependent models suggested a causative effect of leukocytes in the mechanism that triggers thrombosis. The effect of leukocytosis on bleeding (RR, 1.87; 95% CI, 1.26-2.77) and death (RR, 1.89; 95% CI, 1.59-2.23) was confirmed, whereas conclusions on hematologic evolutions and solid tumors were uncertain. To confirm the accuracy of these results, an investigation on individual patient data in a large collective archive of homogeneous patients is warranted.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000211","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:49:08Z","timestamp":1559940548000},"page":"1729-1737","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":154,"title":["Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"3","author":[{"given":"Alessandra","family":"Carobbio","sequence":"first","affiliation":[{"name":"FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5939-8637","authenticated-orcid":false,"given":"Alberto","family":"Ferrari","sequence":"additional","affiliation":[{"name":"FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Masciulli","sequence":"additional","affiliation":[{"name":"FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ghirardi","sequence":"additional","affiliation":[{"name":"FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8357-7192","authenticated-orcid":false,"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Center for the Study of Myelofibrosis, IRCCS Policlinico San Matteo Foundation, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,6,7]]},"reference":[{"issue":"2","key":"2020021108303220500_B1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ajh.23895","article-title":"Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"2020021108303220500_B2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11739-009-0319-3","article-title":"Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia","volume":"5","author":"Vannucchi","year":"2010","journal-title":"Intern Emerg Med"},{"issue":"26","key":"2020021108303220500_B3","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2020021108303220500_B4","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"1","key":"2020021108303220500_B5","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1002\/ajh.24583","article-title":"The effect of arterial hypertension on thrombosis in low-risk polycythemia vera","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2020021108303220500_B6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?","volume":"114","author":"Barbui","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2020021108303220500_B7","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2010.5","article-title":"Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients","volume":"24","author":"Girodon","year":"2010","journal-title":"Leukemia"},{"issue":"9","key":"2020021108303220500_B8","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2020021108303220500_B9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajh.21614","article-title":"Leukocytosis as a risk factor for thrombosis in myeloproliferative neoplasms-biologically plausible but clinically uncertain","volume":"85","author":"Tefferi","year":"2010","journal-title":"Am J Hematol"},{"issue":"16","key":"2020021108303220500_B10","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020021108303220500_B11","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2012-04-424911","article-title":"Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort","volume":"120","author":"Campbell","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2020021108303220500_B12","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2020021108303220500_B13","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2020021108303220500_B14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","article-title":"Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera","volume":"33","author":"Falanga","year":"2005","journal-title":"Exp Hematol"},{"issue":"3-4","key":"2020021108303220500_B15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000175153","article-title":"Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders","volume":"36","author":"Marchetti","year":"2008","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"5","key":"2020021108303220500_B16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"2020021108303220500_B17","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"15","key":"2020021108303220500_B18","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2020021108303220500_B19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jclinepi.2018.01.003","article-title":"Registration in the International Prospective Register of Systematic Reviews (PROSPERO) of systematic review protocols was associated with increased review quality","volume":"100","author":"Sideri","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"2020021108303220500_B20","author":"Wells"},{"issue":"3","key":"2020021108303220500_B21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7109","key":"2020021108303220500_B22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"2020021108303220500_B23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"issue":"1","key":"2020021108303220500_B24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-116-1-78","article-title":"A consumer\u2019s guide to subgroup analyses","volume":"116","author":"Oxman","year":"1992","journal-title":"Ann Intern Med"},{"issue":"4","key":"2020021108303220500_B25","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020021108303220500_B26","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2020021108303220500_B27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ajh.24269","article-title":"Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: evaluation on 1,297 patients","volume":"91","author":"Andriani","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2020021108303220500_B28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/ejh.12759","article-title":"Influence of platelet and white blood cell counts on major thrombosis\u2014analysis from a patient registry in essential thrombocythemia","volume":"97","author":"Buxhofer-Ausch","year":"2016","journal-title":"Eur J Haematol"},{"issue":"6","key":"2020021108303220500_B29","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"issue":"8","key":"2020021108303220500_B30","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-04-153783","article-title":"Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia","volume":"112","author":"Carobbio","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2020021108303220500_B31","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp Hematol"},{"issue":"22","key":"2020021108303220500_B32","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2020021108303220500_B33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/leu.2011.258","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria","volume":"26","author":"Finazzi","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2020021108303220500_B34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"issue":"9","key":"2020021108303220500_B35","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ajh.24788","article-title":"Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease","volume":"92","author":"Jeryczynski","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"2020021108303220500_B36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ajh.23685","article-title":"Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients","volume":"89","author":"Montanaro","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"2020021108303220500_B37","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ajh.24689","article-title":"The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia","volume":"92","author":"Mudireddy","year":"2017","journal-title":"Am J Hematol"},{"issue":"4","key":"2020021108303220500_B38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12185-008-0080-9","article-title":"Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia","volume":"87","author":"Ohyashiki","year":"2008","journal-title":"Int J Hematol"},{"issue":"8","key":"2020021108303220500_B39","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00277-010-1154-3","article-title":"Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study","volume":"90","author":"Palandri","year":"2011","journal-title":"Ann Hematol"},{"issue":"1","key":"2020021108303220500_B40","first-page":"21","article-title":"Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients","volume":"8","author":"Patriarca","year":"2010","journal-title":"Blood Transfus"},{"issue":"4","key":"2020021108303220500_B41","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11739-015-1186-8","article-title":"Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia","volume":"10","author":"Piccin","year":"2015","journal-title":"Intern Emerg Med"},{"issue":"11","key":"2020021108303220500_B42","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ajh.24882","article-title":"Gender and survival in essential thrombocythemia: a two-center study of 1,494 patients","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"2020021108303220500_B43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2020021108303220500_B44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7150\/ijms.10539","article-title":"Impact of JAK2V617F mutation burden on disease phenotype in Chinese patients with JAK2V617F-positive polycythemia vera (PV) and essential thrombocythemia (ET)","volume":"13","author":"Zhao","year":"2016","journal-title":"Int J Med Sci"},{"issue":"8","key":"2020021108303220500_B45","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2020021108303220500_B46","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s12185-008-0188-y","article-title":"Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China","volume":"88","author":"Bai","year":"2008","journal-title":"Int J Hematol"},{"issue":"1","key":"2020021108303220500_B47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"2020021108303220500_B48","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajh.24740","article-title":"Monocytosis in polycythemia vera: clinical and molecular correlates","volume":"92","author":"Barraco","year":"2017","journal-title":"Am J Hematol"},{"issue":"12","key":"2020021108303220500_B49","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","article-title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients","volume":"7","author":"Cerquozzi","year":"2017","journal-title":"Blood Cancer J"},{"issue":"5","key":"2020021108303220500_B50","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/bjh.14625","article-title":"A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera","volume":"177","author":"Enblom-Larsson","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2020021108303220500_B51","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2020021108303220500_B52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2020021108303220500_B53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ejh.12873","article-title":"Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: real-world data from the Swedish MPN Registry","volume":"98","author":"Abdulkarim","year":"2017","journal-title":"Eur J Haematol"},{"issue":"10","key":"2020021108303220500_B54","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00277-009-0706-x","article-title":"Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms","volume":"88","author":"Caramazza","year":"2009","journal-title":"Ann Hematol"},{"issue":"3","key":"2020021108303220500_B55","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ejh.12064","article-title":"Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage","volume":"90","author":"Chou","year":"2013","journal-title":"Eur J Haematol"},{"issue":"3","key":"2020021108303220500_B56","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2020021108303220500_B57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.21593","article-title":"Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia","volume":"85","author":"De Stefano","year":"2010","journal-title":"Am J Hematol"},{"issue":"11","key":"2020021108303220500_B58","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J"},{"issue":"24","key":"2020021108303220500_B59","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1002\/cncr.24664","article-title":"Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera","volume":"115","author":"Gangat","year":"2009","journal-title":"Cancer"},{"issue":"24","key":"2020021108303220500_B60","first-page":"3810","article-title":"Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder\u2014polycythaemia vera and essential thrombocythaemia","volume":"18","author":"P\u00f3sfai","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"2020021108303220500_B61","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/11\/1729\/1631920\/advancesadv2019000211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/11\/1729\/1631920\/advancesadv2019000211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T10:11:01Z","timestamp":1721383861000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/11\/1729\/246702\/Leukocytosis-and-thrombosis-in-essential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,7]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000211","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,7]]}}}